/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | VORVor Biopharma Inc. |
|---|---|
| Last close | $19.86close 2026-11-03 |
| Change % | +3.17%close 2026-11-03 |
| Market cap | $1.2Bclose 2026-11-03 |
| P/E | loss, no P/E |
| Revenue | no revenue filed |
| Rev growth (YoY) | no revenue filed |
| Net income | $-695981000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-130451 · filed 2026-03-30 Open the filing on EDGAR →Open the XBRL payload →CiteVor Biopharma Inc. (VOR), us-gaap:NetIncomeLoss: -695,981,000 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-130451, filed 2026-03-30. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001817229/us-gaap/NetIncomeLoss.json |
| Net margin | not filed |
| EPS (diluted) | $-70.50⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-130451 · filed 2026-03-30 Open the filing on EDGAR →Open the XBRL payload →CiteVor Biopharma Inc. (VOR), us-gaap:EarningsPerShareDiluted: -70.50 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-130451, filed 2026-03-30. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001817229/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | rep. 01-12 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.